UK biotech rais­es £35M to de­vel­op sol­id tu­mor drugs based on ma­chine learn­ing

Lab­Ge­nius has se­cured £35 mil­lion ($44.5 mil­lion) in a Se­ries B raise to ex­pand its an­ti­body dis­cov­ery plat­form and ad­vance a pipeline of can­cer can­di­dates …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER